AN INDIRECT TREATMENT COMPARISON AND COST-EFFECTIVENESS ANALYSIS COMPARING FOLFIRINOX WITH NAB-PACLITAXEL PLUS GEMCITABINE FOR FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC PANCREATIC CANCER

被引：4
|
作者：
Hollmann, S. [1 ]
Alloul, K. [2 ]
Attard, C. [1 ]
Kavan, P. [3 ]
机构：
[1] Cornerstone Res Grp, Burlington, ON, Canada
[2] Sanofi Canada, Laval, PQ, Canada
[3] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr E 715, Montreal, PQ H3T 1E2, Canada
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu164.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 0018
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer Propensity Score Matching
    Mie, Takafumi
    Sasaki, Takashi
    Takeda, Tsuyoshi
    Fukuda, Koshiro
    Furukawa, Takaaki
    Yamada, Yuto
    Kasuga, Akiyoshi
    Matsuyama, Masato
    Ozaka, Masato
    Sasahira, Naoki
    PANCREAS, 2021, 50 (04) : 595 - 601
  • [42] Treatment outcomes with first-line (1L) nab-Paclitaxel plus gemcitabine (AG) and FOLFIRINOX (FFX) in metastatic pancreatic adenocarcinoma (mPAC).
    Cartwright, Thomas H.
    Parisi, Monika
    Espirito, Janet L.
    Wilson, Thomas
    Pelletier, Corey
    Patel, Manish
    Babiker, Hani M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
    Riedl, J. M.
    Posch, F.
    Horvath, L.
    Gantschnigg, A.
    Renneberg, F.
    Schwarzenbacher, E.
    Moik, F.
    Barth, D.
    Stotz, M.
    Schaberl-Moser, R.
    Pichler, M.
    Stoeger, H.
    Greil, R.
    Djanani, A.
    Schlick, K.
    Gerger, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S942 - S942
  • [44] Gemcitabine plus nab-paclitaxel followed by maintenance treatment with gemcitabine alone as first-line treatment for older adults with locally advanced or metastatic pancreatic cancer
    Petrioli, Roberto
    Torre, Pamela
    Pesola, Guido
    Paganini, Giovanni
    Paolelli, Loretta
    Miano, Salvatora Tindara
    Martellucci, Ignazio
    Francini, Guido
    Francini, Edoardo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (04) : 647 - 651
  • [45] First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
    Vivaldi, Caterina
    Salani, Francesca
    Rovesti, Giulia
    Pecora, Irene
    Catanese, Silvia
    Casadei-Gardini, Andrea
    Massa, Valentina
    Bernardini, Laura
    Riggi, Laura
    Andrikou, Kalliopi
    Rapposelli, Giovanni I.
    Formica, Vincenzo
    Lencioni, Monica
    Falcone, Alfredo
    Vasile, Enrico
    Fornaro, Lorenzo
    EUROPEAN JOURNAL OF CANCER, 2020, 137 : 108 - 116
  • [46] Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX
    McBride, Ali
    Bonafede, Machaon
    Cai, Qian
    Princic, Nicole
    Tran, Oth
    Pelletier, Corey
    Parisi, Monika
    Patel, Manish
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) : 1153 - 1160
  • [47] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Lei Yang
    Jing Su
    Wenbo Wang
    Fuxiang Zhou
    World Journal of Surgical Oncology, 21
  • [48] The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study
    Yang, Lei
    Su, Jing
    Wang, Wenbo
    Zhou, Fuxiang
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2023, 21 (01)
  • [49] Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
    Mita, Naoki
    Iwashita, Takuji
    Uemura, Shinya
    Yoshida, Kensaku
    Iwasa, Yuhei
    Ando, Nobuhiro
    Iwata, Keisuke
    Okuno, Mitsuru
    Mukai, Tsuyoshi
    Shimizu, Masahito
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [50] Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients
    Ingram, Myles A.
    Lauren, Brianna N.
    Pumpalova, Yoanna
    Park, Jiheum
    Lim, Francesca
    Bates, Susan E.
    Kastrinos, Fay
    Manji, Gulam A.
    Kong, Chung Yin
    Hur, Chin
    CANCER REPORTS, 2022, 5 (09)
12345